Modified Diagnosis and Treatment of Neonatal Hemolysis With ETCOc in sNH

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Neonatal Hyperbilirubinemia
Interventions
COMBINATION_PRODUCT

MDT

"(actually not combination product, but have to select that option in order to delete warning in study desine)MDT method for sNH with the description as follow: 1. diagnosis of neonatal hemolysis:~The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they met one criterion from Category A or two criteria from Category B:~Category A:~1. Positive DAT~2. Significantly elevated ETCOc;~3. Significant morphological abnormalities~Category B:~1. Positive release test;~2. Elevated ETCOc;~3. COHb \> 1.2%;~4. Hb \< 140 g/L or Hct) \< 40%;~5. Ret \> 6%. 2.Exchange transfusion (ET) therapy for sNH: any of the following criteria are met:~(1) TSB ≥ the current ET threshold; (2) TSB \> (ET - 2) mg/dL or the increase of TSB \> 0.5 mg/dL/h, accompanied by abnormal aEEG findings; (3) TSB \> (ET - 2) mg/dL or \> 0.5 mg/dL/h, accompanied by a BIND score of 4-6; (4) Presence of clinical manifestations of acute ABE; (5) BIND score of 7-9."

OTHER

control (current management)

"Control (current) method for sNH (severe neonatal hemolysis) with the description as follow:~1. Diagnosis of neonatal hemolysis: The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they have positive Direct Antiglobulin Test (DAT) or positive release test result.~2. Exchange transfusion (ET) therapy for sNH: The neonatal subjects with symptom of hyperbilirubinemia are treated with ET therapy if their Total serum bilirubin (TSB) reaches or exceeds the current exchange transfusion threshold;"

All Listed Sponsors
lead

Women's Hospital School Of Medicine Zhejiang University

OTHER